In the global pharmaceutical industry, the expiration of a molecule’s active compound patent is only the first hurdle. The true gateway to high-margin generic entry is navigating Formulation and Composition Patents.
Originator companies frequently layer secondary patents—covering crystalline polymorphs, specialized drug delivery mechanisms, stable liquid concentrations, or fixed-dose combinations—to extend market exclusivity long after the primary chemical entity patent has expired.
For global generic manufacturers, marketers, and Business Development (BD) teams, capturing market share requires tracking exactly when these formulation constraints dissolve. Whether targeting recently unprotected multi-billion dollar markets or preparing for the upcoming wave, leveraging strategic B2B licensing frameworks allows companies to access non-infringing formulation pathways already validated by expert networks.
The Master Sourcing Pipeline: Blockbuster Formulation & Composition Patent Milestones (2024–2031)
To successfully plan your portfolio expansion, your business development strategies must align with both immediate market entries and mid-term product development cycles. Below is the comprehensive sequential roadmap of major blockbuster assets losing crucial formulation or composition protection:
| Year of Expiry | Brand Name | Active Pharmaceutical Ingredient (API) | Primary Therapeutic Category | Specific Formulation Type / Delivery System |
|---|---|---|---|---|
| 2024 | Vyvanse® | Lisdexamfetamine dimesylate | CNS / ADHD | Soluble Oral Capsule and Chewable Tablet Composition |
| 2024 | Symbicort® | Budesonide / Formoterol | Respiratory | Metered Dose Inhaler (MDI) Suspension Formulation |
| 2024 | Paxlovid® | Nirmatrelvir / Ritonavir | Antiviral | Co-packaged Immediate-Release Oral Solid Film-Coated Matrix |
| 2025 | Victoza® | Liraglutide | Metabolic (Diabetes) | Stabilized Aqueous Solution for Subcutaneous Injection Pen |
| 2025 | Sprycel® | Dasatinib | Oncology | Crystalline Monohydrate Film-Coated Oral Tablet |
| 2025 | Pomalyst® | Pomalidomide | Oncology | Low-Dose Solid Oral Capsule Dispersion Matrix |
| 2025 | Mirena® | Levonorgestrel | Women's Health | Intrauterine Drug Delivery System with Silicone Membrane |
| 2026 | Pradaxa® | Dabigatran etexilate mesylate | Cardiovascular | Tartaric Acid Core Pellet Oral Capsule Formulation |
| 2026 | Invega Sustenna® | Paliperidone palmitate | Psychiatry | Extended-Release Aqueous Injection Suspension |
| 2026 | Xarelto® | Rivaroxaban | Cardiovascular | Immediate-Release Compressed Oral Granulation Matrix |
| 2027 | Keytruda® | Pembrolizumab | Oncology | Stabilized Liquid Monoclonal Antibody Injection |
| 2027 | Entresto® | Sacubitril / Valsartan | Cardiovascular | Dual-acting Amorphous Co-crystal Solid Oral Form |
| 2027 | Eylea® | Aflibercept | Ophthalmology | Iso-osmotic Intravitreal Solution Pre-filled Syringe |
| 2027 | Ofev® | Nintedanib | Respiratory | Soft Gelatin Capsule Suspension Formulation |
| 2027 | Aubagio® | Teriflunomide | Neurology (MS) | Film-coated Tablets with Specific Core Excipients |
| 2027 | Trodelvy® | Sacituzumab govitecan | Oncology | Lyophilized Powder Form for Intravenous Infusion |
| 2027 | Galafold® | Migalastat | Rare Disease | Immediate-release Oral Capsule Composition |
| 2028 | Imbruvica® | Ibrutinib | Oncology | High-dose Hard Gelatin Oral Capsule Matrix |
| 2028 | Revlimid® | Lenalidomide | Oncology | Polymorphic Form Capsule Composition Optimization |
| 2028 | Jakafi® | Ruxolitinib | Oncology / Immunology | Phosphate Salt Tablet Form with Specific Disintegration |
| 2028 | Shingrix® | Zoster Vaccine Recombinant | Infectious Disease | Adjuvanted Liposomal Lyophilized Suspension |
| 2028 | Praluent® | Alirocumab | Cardiovascular | Aqueous Monoclonal Antibody Pen-Injector Formulation |
| 2028 | Erleada® | Apalutamide | Oncology | Solid Dispersion Formulation for Bioavailability |
| 2029 | Eliquis® | Apixaban | Cardiovascular | Solubilized Tablet Formulation using Crystalline API |
| 2029 | Jardiance® | Empagliflozin | Metabolic | Immediate-release Compressed Tablet Formulation |
| 2029 | Biktarvy® | Bictegravir / Emtricitabine / TAF | Antiviral (HIV) | Fixed-dose Multi-layered Combination Tablet |
| 2029 | Brilinta® | Ticagrelor | Cardiovascular | Hydrophilic Coating Oral Solid Formulation |
| 2029 | Linzess® / Constella® | Linaclotide | Gastroenterology | Acid-stable Solid Peptide Oral Capsule Matrix |
| 2029 | Simponi® | Golimumab | Immunology | High-concentration Subcutaneous Injection Auto-injector |
| 2029 | Tagrisso® | Osimertinib | Oncology (NSCLC) | Mesylate Salt Compressed Core Tablet Composition |
| 2030 | Stelara® | Ustekinumab | Immunology | Preservative-free Monoclonal Antibody Solution |
| 2030 | Ozempic® / Wegovy® | Semaglutide | Metabolic | Propylene Glycol Stabilized Subcutaneous Peptide Solution |
| 2030 | Farxiga® / Forxiga® | Dapagliflozin | Metabolic / Cardiovascular | Crystalline Lactose Anhydrous Tablet Formulation |
| 2030 | Vyndaqel® / Vyndamax® | Tafamidis | Cardiovascular | Micronized API Suspension in Soft Gelatin Capsules |
| 2030 | Entyvio® | Vedolizumab | Gastroenterology | Lyophilized Cake Formulation for Reconstitution |
| 2030 | Ocrevus® | Ocrelizumab | Neurology | Sodium Acetate Trihydrate Buffered Injection Fluid |
| 2030 | Cosentyx® | Secukinumab | Immunology | High-viscosity Liquid Solution in Ready-to-Use Pens |
| 2031 | Ibrance® | Palbociclib | Oncology | Free Base Capsule Form vs. Improved Tablet Formulations |
| 2031 | Prolia® / Xgeva® | Denosumab | Endocrinology / Oncology | Sorbitol-stabilized Aqueous Monoclonal Antibody Liquid |
| 2031 | Mounjaro® / Zepbound® | Tirzepatide | Metabolic | Multi-dose or Single-dose Peptide Sterile Aqueous Blend |
| 2031 | Lynparza® | Olaparib | Oncology | Lipid-based Hot-melt Extrusion Polymeric Tablet Matrix |
| 2031 | Spinraza® | Nusinersen | Neurology | Intrathecal Phosphate-buffered Saline Formulation |
| 2031 | Nucala® | Mepolizumab | Respiratory | Sucrose-bulked Lyophilized Formulation for Injection |
B2B Sourcing Mechanisms: Accelerating Entry via Strategic Licensing
Bypassing complex composition hurdles and capturing market share—whether for immediate rollouts of recently off-patent molecules or future launches—requires structured B2B licensing pathways:
- Dossier In-Licensing (The Marketer's Fast-Track): Regional Marketing Authorization Holders (MAHs) buy the rights to ready-to-submit Common Technical Documents (CTD/eCTD) from external developers. By in-licensing dossiers for products like Apixaban or Liraglutide, brands completely eliminate years of formulation trials and bioequivalence (BE) risks.
- Commercial Out-Licensing (The Developer’s Scale-Up): Asset developers who have engineered robust, non-infringing delivery platforms (e.g., specific soft-gel suspensions or crystalline variants) out-license these files to regional distributors. This expands commercial footprints across markets like the EU, LATAM, and MENA without physical expansion.
- Strategic Co-Development & Technology Transfer: Intricate drug delivery systems—such as the complex peptide matrices for Semaglutide—carry high stability risks. A co-development framework splits the developmental burden, leveraging Process Analytical Technology (PAT) to transfer scaled-up industrial batches cleanly to manufacturing networks.
A Message to Global Pharma Partners: Build Your Portfolio with PharpleQ
Are you positioned to dominate both current openings and the upcoming patent wave?
Delays in analyzing and reverse-engineering complex drug formulation frameworks translate directly to lost market share and missed first-to-market advantages. Whether your company is looking to in-license fully validated generic dossiers to capture immediate expiries, seek out-licensing partners for cross-border pipeline commercialization, or initiate a complex technology transfer for upcoming blockbusters, PharpleQ Lifesciences is your strategic B2B orchestration partner.
Through our deeply vetted network of global associated manufacturing partners, we provide access to audited manufacturing infrastructure, fully compiled CMC documentation, and non-infringing formulation pathways.
Don't wait for your competition to capture the market.
Contact PharpleQ Lifesciences team today to check dossier availability for recently off-patent products or secure your slot for the 2027–2031 pipeline.